EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Jan. 3, 2006--Savient Pharmaceuticals, Inc. (NASDAQ: SVNTE), an emerging specialty pharmaceuticals company focused on developing, manufacturing and marketing novel therapeutic products for unmet medical needs, announced today that the Nasdaq Listing Qualifications Panel (the Panel) has agreed to continue the listing of the Company’s securities on The Nasdaq National Market provided that the Company files its Form 10-K for the year ended December 31, 2004, including 2003, 2002 and 2001 prior period restatements, and Form 10-Q for the quarter ended March 31, 2005, as well as its initial Form 10-Q for the quarter ended June 30, 2005, by January 13, 2006, and provided that Savient also files by January 20, 2006 its Form 10-Q for the quarter ended September 30, 2005.
